Abstract
Giant cell arteritis (GCA) is a systemic vasculitis in individuals older than 50 years, characterized by headaches, visual disturbances, painful scalp, jaw claudication, impairment of limb arteries, and systemic inflammation, among other symptoms. GCA diagnosis is confirmed by a positive temporal artery biopsy (TAB) or by imaging modalities. A prominent acute phase response with inflammation is the hallmark of the disease, predominantly targeting large- and medium-sized arteries leading to stenosis or occlusion of arterial lumen. To date, there are no reliable tissue markers specific for GCA. Scarce reports have indicated the importance of epigenetics in GCA. The current systematic review reports significantly changed candidate biomarkers in TABs of GCA patients compared to non-GCA patients using qPCR.
Similar content being viewed by others
References
Dejaco C, Brouwer E, Mason JC, Buttgereit F, Matteson EL, Dasgupta B (2017) Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. Nat Rev Rheumatol 13(10):578–592. https://doi.org/10.1038/nrrheum.2017.142
Makol A, Matteson EL (2012) Utility of C-reactive protein in the diagnosis of giant cell arteritis: better than the erythrocyte sedimentation rate? Int J Clin Rheumatol 7(3):247–250
De Smit E, Clarke L, Sanfilippo PG, Merriman TR, Brown MA, Hill CL, Hewitt AW (2017) Geo-epidemiology of temporal artery biopsy-positive giant cell arteritis in Australia and New Zealand: is there a seasonal influence? RMD Open 3(2):e000531. https://doi.org/10.1136/rmdopen-2017-000531
Samson M, Corbera-Bellalta M, Audia S, Planas-Rigol E, Martin L, Cid MC, Bonnotte B (2017) Recent advances in our understanding of giant cell arteritis pathogenesis. Autoimmun Rev 16(8):833–844. https://doi.org/10.1016/j.autrev.2017.05.014
Guevara M, Kollipara CS (2018) Recent advances in Giant cell arteritis. Curr Rheumatol Rep 20(5):25. https://doi.org/10.1007/s11926-018-0737-1
Zhang H, Watanabe R, Berry GJ, Vaglio A, Liao YJ, Warrington KJ, Goronzy JJ, Weyand CM (2017) Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proc Natl Acad Sci U S A 114(6):E970–E979. https://doi.org/10.1073/pnas.1616848114
Weyand CM, Berry GJ, Goronzy JJ (2018) The immunoinhibitory PD-1/PD-L1 pathway in inflammatory blood vessel disease. J Leukoc Biol 103(3):565–575. https://doi.org/10.1189/jlb.3MA0717-283
Watanabe R, Zhang H, Berry G, Goronzy JJ, Weyand CM (2017) Immune checkpoint dysfunction in large and medium vessel vasculitis. Am J Physiol Heart Circ Physiol 312(5):H1052–H1059. https://doi.org/10.1152/ajpheart.00024.2017
Samson M, Audia S, Fraszczak J, Trad M, Ornetti P, Lakomy D, Ciudad M, Leguy V, Berthier S, Vinit J, Manckoundia P, Maillefert JF, Besancenot JF, Aho-Glele S, Olsson NO, Lorcerie B, Guillevin L, Mouthon L, Saas P, Bateman A, Martin L, Janikashvili N, Larmonier N, Bonnotte B (2012) Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum 64(11):3788–3798. https://doi.org/10.1002/art.34647
van der Geest KS, Abdulahad WH, Chalan P, Rutgers A, Horst G, Huitema MG, Roffel MP, Roozendaal C, Kluin PM, Bos NA, Boots AM, Brouwer E (2014) Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica. Arthritis Rheumatol 66(7):1927–1938. https://doi.org/10.1002/art.38625
Ciccia F, Rizzo A, Ferrante A, Guggino G, Croci S, Cavazza A, Salvarani C, Triolo G (2017) New insights into the pathogenesis of giant cell arteritis. Autoimmun Rev 16(7):675–683. https://doi.org/10.1016/j.autrev.2017.05.004
Dejaco C, Ramiro S, Duftner C, Besson FL, Bley TA, Blockmans D, Brouwer E, Cimmino MA, Clark E, Dasgupta B, Diamantopoulos AP, Direskeneli H, Iagnocco A, Klink T, Neill L, Ponte C, Salvarani C, Slart R, Whitlock M, Schmidt WA (2018) EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis 77(5):636–643. https://doi.org/10.1136/annrheumdis-2017-212649
Carmona FD, Martin J, Gonzalez-Gay MA (2015) Genetics of vasculitis. Curr Opin Rheumatol 27(1):10–17. https://doi.org/10.1097/BOR.0000000000000124
Carmona FD, Vaglio A, Mackie SL, Hernandez-Rodriguez J, Monach PA, Castaneda S, Solans R, Morado IC, Narvaez J, Ramentol-Sintas M, Pease CT, Dasgupta B, Watts R, Khalidi N, Langford CA, Ytterberg S, Boiardi L, Beretta L, Govoni M, Emmi G, Bonatti F, Cimmino MA, Witte T, Neumann T, Holle J, Schonau V, Sailler L, Papo T, Haroche J, Mahr A, Mouthon L, Molberg O, Diamantopoulos AP, Voskuyl A, Brouwer E, Daikeler T, Berger CT, Molloy ES, O'Neill L, Blockmans D, Lie BA, McLaren P, Vyse TJ, Wijmenga C, Allanore Y, Koeleman BPC, Barrett JH, Cid MC, Salvarani C, Merkel PA, Morgan AW, Gonzalez-Gay MA, Martin J (2017) A genome-wide association study identifies risk alleles in plasminogen and P4HA2 associated with Giant cell arteritis. Am J Hum Genet 100(1):64–74. https://doi.org/10.1016/j.ajhg.2016.11.013
Serrano A, Marquez A, Mackie SL, Carmona FD, Solans R, Miranda-Filloy JA, Hernandez-Rodriguez J, Cid MC, Castaneda S, Morado IC, Narvaez J, Blanco R, Sopena B, Garcia-Villanueva MJ, Monfort J, Ortego-Centeno N, Unzurrunzaga A, Mari-Alfonso B, Sanchez Martin J, de Miguel E, Magro C, Raya E, Braun N, Latus J, Molberg O, Lie BA, Moosig F, Witte T, Morgan AW, Gonzalez-Gay MA, Martin J (2013) Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis. Ann Rheum Dis 72(11):1882–1886. https://doi.org/10.1136/annrheumdis-2013-203641
Bird A (2007) Perceptions of epigenetics. Nature 447(7143):396–398. https://doi.org/10.1038/nature05913
Lai WKM, Pugh BF (2017) Understanding nucleosome dynamics and their links to gene expression and DNA replication. Nat Rev Mol Cell Biol 18(9):548–562. https://doi.org/10.1038/nrm.2017.47
Coit P, Direskeneli H, Sawalha AH (2018) An update on the role of epigenetics in systemic vasculitis. Curr Opin Rheumatol 30(1):4–15. https://doi.org/10.1097/BOR.0000000000000451
Jeltsch A, Jurkowska RZ (2014) New concepts in DNA methylation. Trends Biochem Sci 39(7):310–318. https://doi.org/10.1016/j.tibs.2014.05.002
Dawson MA, Kouzarides T (2012) Cancer epigenetics: from mechanism to therapy. Cell 150(1):12–27. https://doi.org/10.1016/j.cell.2012.06.013
Frank-Bertoncelj M, Gay S (2014) The epigenome of synovial fibroblasts: an underestimated therapeutic target in rheumatoid arthritis. Arthritis Res Ther 16(3):117. https://doi.org/10.1186/ar4596
Allis CD, Jenuwein T (2016) The molecular hallmarks of epigenetic control. Nat Rev Genet 17(8):487–500. https://doi.org/10.1038/nrg.2016.59
Klein K, Kabala PA, Grabiec AM, Gay RE, Kolling C, Lin LL, Gay S, Tak PP, Prinjha RK, Ospelt C, Reedquist KA (2016) The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts. Ann Rheum Dis 75(2):422–429. https://doi.org/10.1136/annrheumdis-2014-205809
Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, Chandwani R, Marazzi I, Wilson P, Coste H, White J, Kirilovsky J, Rice CM, Lora JM, Prinjha RK, Lee K, Tarakhovsky A (2010) Suppression of inflammation by a synthetic histone mimic. Nature 468(7327):1119–1123. https://doi.org/10.1038/nature09589
Karlsson O, Baccarelli AA (2016) Environmental health and long non-coding RNAs. Curr Environ Health Rep 3(3):178–187. https://doi.org/10.1007/s40572-016-0092-1
Sato F, Tsuchiya S, Meltzer SJ, Shimizu K (2011) MicroRNAs and epigenetics. FEBS J 278(10):1598–1609. https://doi.org/10.1111/j.1742-4658.2011.08089.x
Burja B, Kuret T, Sodin-Semrl S, Lakota K, Rotar Z, Jese R, Mrak-Poljsak K, Zigon P, Thallinger GG, Feichtinger J, Cucnik S, Tomsic M, Praprotnik S, Hocevar A (2018) A concise review of significantly modified serological biomarkers in giant cell arteritis, as detected by different methods. Autoimmun Rev 17(2):188–194. https://doi.org/10.1016/j.autrev.2017.11.022
Lakota K, Feichtinger J, Burja B, Kuret T, Žigon P, Rotar Ž, Ješe R, Sodin-Šemrl S, Čučnik S, Thallinger G, Tomšič M, Hočevar A (2017) Utility of serological parameters in giant cell arteritis for predicting disease complications. Ann Rheum Dis 76:219
Weyand CM, Hicok KC, Hunder GG, Goronzy JJ (1994) Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 121(7):484–491
Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM (2010) Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 121(7):906–915. https://doi.org/10.1161/CIRCULATIONAHA.109.872903
Hernández-Rodríguez J, Segarra M, Vilardell C, Sánchez M, García-Martínez A, Esteban MJ, Queralt C, Grau JM, Urbano-Márquez A, Palacín A, Colomer D, Cid MC (2004) Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 43(3):294–301. https://doi.org/10.1093/rheumatology/keh058
Ciccia F, Rizzo A, Guggino G, Cavazza A, Alessandro R, Maugeri R, Cannizzaro A, Boiardi L, Iacopino DG, Salvarani C, Triolo G (2015) Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis. Rheumatology (Oxford) 54(9):1596–1604. https://doi.org/10.1093/rheumatology/kev102
Ciccia F, Alessandro R, Rizzo A, Principe S, Raiata F, Cavazza A, Guggino G, Accardo-Palumbo A, Boiardi L, Ferrante A, Principato A, Giardina A, De Leo G, Salvarani C, Triolo G (2011) Expression of interleukin-32 in the inflamed arteries of patients with giant cell arteritis. Arthritis Rheum 63(7):2097–2104. https://doi.org/10.1002/art.30374
Ciccia F, Rizzo A, Maugeri R, Alessandro R, Croci S, Guggino G, Cavazza A, Raimondo S, Cannizzaro A, Iacopino DG, Salvarani C, Triolo G (2016) Ectopic expression of CXCL13, BAFF, APRIL and LT-β is associated with artery tertiary lymphoid organs in giant cell arteritis. Ann Rheum Dis 76(1):235–243. https://doi.org/10.1136/annrheumdis-2016-209217
Ciccia F, Alessandro R, Rizzo A, Raimondo S, Giardina A, Raiata F, Boiardi L, Cavazza A, Guggino G, De Leo G, Salvarani C, Triolo G (2013) IL-33 is overexpressed in the inflamed arteries of patients with giant cell arteritis. Ann Rheum Dis 72(2):258–264. https://doi.org/10.1136/annrheumdis-2012-201309
Espígol-Frigolé G, Corbera-Bellalta M, Planas-Rigol E, Lozano E, Segarra M, García-Martínez A, Prieto-González S, Hernández-Rodríguez J, Grau JM, Rahman MU, Cid MC (2013) Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis. Ann Rheum Dis 72(9):1481–1487. https://doi.org/10.1136/annrheumdis-2012-201836
Corbera-Bellalta M, García-Martínez A, Lozano E, Planas-Rigol E, Tavera-Bahillo I, Alba MA, Prieto-González S, Butjosa M, Espígol-Frigolé G, Hernández-Rodríguez J, Fernández PL, Roux-Lombard P, Dayer JM, Rahman MU, Cid MC (2014) Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis. Ann Rheum Dis 73(3):616–623. https://doi.org/10.1136/annrheumdis-2012-202883
Lakota K, Kuret T, Žigon P, Rotar Ž, Tomšič M, Čučnik S, Sodin-Šemrl S, Hočevar A (2015) Biomarkers in temporal artery biopsies and sera of patients with giant cell arteritis. Arthritis Rheumatology 67(suppl 10)
Segarra M, García-Martínez A, Sánchez M, Hernández-Rodríguez J, Lozano E, Grau JM, Cid MC (2007) Gelatinase expression and proteolytic activity in giant-cell arteritis. Ann Rheum Dis 66(11):1429–1435. https://doi.org/10.1136/ard.2006.068148
Rodríguez-Pla A, Martínez-Murillo F, Savino PJ, Eagle RC, Seo P, Soloski MJ (2009) MMP-12, a novel matrix metalloproteinase associated with giant cell arteritis. Rheumatology (Oxford) 48(11):1460–1461. https://doi.org/10.1093/rheumatology/kep271
Lozano E, Segarra M, Corbera-Bellalta M, García-Martínez A, Espígol-Frigolé G, Plà-Campo A, Hernández-Rodríguez J, Cid MC (2010) Increased expression of the endothelin system in arterial lesions from patients with giant-cell arteritis: association between elevated plasma endothelin levels and the development of ischaemic events. Ann Rheum Dis 69(2):434–442. https://doi.org/10.1136/ard.2008.105692
Visvanathan S, Rahman MU, Hoffman GS, Xu S, García-Martínez A, Segarra M, Lozano E, Espígol-Frigolé G, Hernández-Rodríguez J, Cid MC (2011) Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis--a prospective longitudinal study. Rheumatology (Oxford) 50(11):2061–2070. https://doi.org/10.1093/rheumatology/ker163
Manku S, Wong W, Luo Z, Seidman MA, Alabdurubalnabi Z, Rey K, Enns W, Avina-Zubieta JA, Shojania K, Choy JC (2018) IL-6 expression is correlated with increased T-cell proliferation and survival in the arterial wall in giant cell arteritis. Cardiovasc Pathol 33:55–61. https://doi.org/10.1016/j.carpath.2018.01.004
Zerbini A, Muratore F, Boiardi L, Ciccia F, Bonacini M, Belloni L, Cavazza A, Cimino L, Moramarco A, Alessandro R, Rizzo A, Parmeggiani M, Salvarani C, Croci S (2018) Increased expression of interleukin-22 in patients with giant cell arteritis. Rheumatology (Oxford) 57(1):64–72. https://doi.org/10.1093/rheumatology/kex334
Regent A, Ly KH, Groh M, Khifer C, Lofek S, Clary G, Chafey P, Baud V, Broussard C, Federici C, Labrousse F, Mesturoux L, Le Jeunne C, Vidal E, Brezin A, Witko-Sarsat V, Guillevin L, Mouthon L (2017) Molecular analysis of vascular smooth muscle cells from patients with giant cell arteritis: targeting endothelin-1 receptor to control proliferation. Autoimmun Rev 16(4):398–406. https://doi.org/10.1016/j.autrev.2017.02.006
Coit P, De Lott LB, Nan B, Elner VM, Sawalha AH (2016) DNA methylation analysis of the temporal artery microenvironment in giant cell arteritis. Ann Rheum Dis 75(6):1196–1202. https://doi.org/10.1136/annrheumdis-2014-207116
Croci S, Zerbini A, Boiardi L, Muratore F, Bisagni A, Nicoli D, Farnetti E, Pazzola G, Cimino L, Moramarco A, Cavazza A, Casali B, Parmeggiani M, Salvarani C (2016) MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis. Ann Rheum Dis 75(8):1527–1533. https://doi.org/10.1136/annrheumdis-2015-207846
Kermani TA, Dasgupta B (2017) Current and emerging therapies in large-vessel vasculitis. Rheumatology. https://doi.org/10.1093/rheumatology/kex385
Ciechomska M, O'Reilly S (2016) Epigenetic modulation as a therapeutic Prospect for treatment of autoimmune rheumatic diseases. Mediat Inflamm 2016:9607946–9607911. https://doi.org/10.1155/2016/9607946
Funding
Funding for this work was obtained from the Slovenian Research Agency for the National Research Programme #P3-0314, the Austrian Ministry of Science, Research and Economy (HSRSM project OMICS Center Graz), and the Austrian Science Fund (FWF): T923-B26.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Disclosures
None.
Ethical approval and consent to participate
Not applicable.
Consent for publication
All authors give consent for publication.
Additional information
Tadeja Kuret and Blaž Burja shared first authorship
Rheumatology in Slovenia: Clinical practice and translational research
Rights and permissions
About this article
Cite this article
Kuret, T., Burja, B., Feichtinger, J. et al. Gene and miRNA expression in giant cell arteritis—a concise systematic review of significantly modified studies. Clin Rheumatol 38, 307–316 (2019). https://doi.org/10.1007/s10067-018-4231-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-018-4231-y